BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 27338099)

  • 1. Targeting Epstein-Barr virus-transformed B lymphoblastoid cells using antibodies with T-cell receptor-like specificities.
    Lai J; Tan WJ; Too CT; Choo JA; Wong LH; Mustafa FB; Srinivasan N; Lim AP; Zhong Y; Gascoigne NR; Hanson BJ; Chan SH; Chen J; MacAry PA
    Blood; 2016 Sep; 128(10):1396-407. PubMed ID: 27338099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TCR-like antibodies mediate complement and antibody-dependent cellular cytotoxicity against Epstein-Barr virus-transformed B lymphoblastoid cells expressing different HLA-A*02 microvariants.
    Lai J; Choo JAL; Tan WJ; Too CT; Oo MZ; Suter MA; Mustafa FB; Srinivasan N; Chan CEZ; Lim AGX; Zhong Y; Chan SH; Hanson BJ; Gascoigne NRJ; MacAry PA
    Sci Rep; 2017 Aug; 7(1):9923. PubMed ID: 28855662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TCR-mimic bispecific antibodies targeting LMP2A show potent activity against EBV malignancies.
    Ahmed M; Lopez-Albaitero A; Pankov D; Santich BH; Liu H; Yan S; Xiang J; Wang P; Hasan AN; Selvakumar A; O'Reilly RJ; Liu C; Cheung NV
    JCI Insight; 2018 Feb; 3(4):. PubMed ID: 29467338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Defining the expression hierarchy of latent T-cell epitopes in Epstein-Barr virus infection with TCR-like antibodies.
    Sim AC; Too CT; Oo MZ; Lai J; Eio MY; Song Z; Srinivasan N; Tan DA; Pang SW; Gan SU; Lee KO; Loh TK; Chen J; Chan SH; MacAry PA
    Sci Rep; 2013 Nov; 3():3232. PubMed ID: 24240815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generation of functional human T-cell subsets with HLA-restricted immune responses in HLA class I expressing NOD/SCID/IL2r gamma(null) humanized mice.
    Shultz LD; Saito Y; Najima Y; Tanaka S; Ochi T; Tomizawa M; Doi T; Sone A; Suzuki N; Fujiwara H; Yasukawa M; Ishikawa F
    Proc Natl Acad Sci U S A; 2010 Jul; 107(29):13022-7. PubMed ID: 20615947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting TfR1 with the ch128.1/IgG1 Antibody Inhibits EBV-driven Lymphomagenesis in Immunosuppressed Mice Bearing EBV
    Martínez LE; Daniels-Wells TR; Guo Y; Magpantay LI; Candelaria PV; Penichet ML; Martínez-Maza O; Epeldegui M
    Mol Cancer Ther; 2021 Sep; 20(9):1592-1602. PubMed ID: 34158342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes home preferentially to and induce selective regressions of autologous EBV-induced B cell lymphoproliferations in xenografted C.B-17 scid/scid mice.
    Lacerda JF; Ladanyi M; Louie DC; Fernandez JM; Papadopoulos EB; O'Reilly RJ
    J Exp Med; 1996 Mar; 183(3):1215-28. PubMed ID: 8642263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epstein-Barr virus, B cell lymphoproliferative disease, and SCID mice: modeling T cell immunotherapy in vivo.
    Johannessen I; Bieleski L; Urquhart G; Watson SL; Wingate P; Haque T; Crawford DH
    J Med Virol; 2011 Sep; 83(9):1585-96. PubMed ID: 21739450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Ex vivo inducing cultured Epstein-Barr virus specific cytotoxic T lymphocytes and evaluation of their killing effect].
    Chen GH; Gu B; Chen F; Wang Y; Qiao M; Liu HW; Feng YF; Dai LJ; Zhu ZL; Wu DP
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Dec; 21(6):1597-601. PubMed ID: 24370055
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of antiviral cytotoxic T cells by plasmacytoid dendritic cells for adoptive immunotherapy of posttransplant diseases.
    Aspord C; Laurin D; Richard MJ; Vie H; Chaperot L; Plumas J
    Am J Transplant; 2011 Dec; 11(12):2613-26. PubMed ID: 21883919
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune reconstitution of HLA-A*0201/BMLF1- and HLA-A*1101/LMP2-specific Epstein Barr virus cytotoxic T lymphocytes within 90 days after haploidentical hematopoietic stem cell transplantation.
    Zhou L; Lu DP
    Virol J; 2019 Feb; 16(1):19. PubMed ID: 30736814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Attenuated immune control of Epstein-Barr virus in humanized mice is associated with the multiple sclerosis risk factor HLA-DR15.
    Zdimerova H; Murer A; Engelmann C; Raykova A; Deng Y; Gujer C; Rühl J; McHugh D; Caduff N; Naghavian R; Pezzino G; Capaul R; Zbinden A; Ferlazzo G; Lünemann JD; Martin R; Chatterjee B; Münz C
    Eur J Immunol; 2021 Jan; 51(1):64-75. PubMed ID: 32949466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adoptive transfer of cytotoxic T lymphocytes for the treatment of transplant-associated lymphoma.
    Boyle TJ; Berend KR; DiMaio JM; Coles RE; Via DF; Lyerly HK
    Surgery; 1993 Aug; 114(2):218-25; discussion 226. PubMed ID: 8393595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dendritic cells improve the generation of Epstein-Barr virus-specific cytotoxic T lymphocytes for the treatment of posttransplantation lymphoma.
    Wheatley GH; McKinnon KP; Iacobucci M; Mahon S; Gelber C; Lyerly HK
    Surgery; 1998 Aug; 124(2):171-6. PubMed ID: 9706135
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CDR3α drives selection of the immunodominant Epstein Barr virus (EBV) BRLF1-specific CD8 T cell receptor repertoire in primary infection.
    Kamga L; Gil A; Song I; Brody R; Ghersi D; Aslan N; Stern LJ; Selin LK; Luzuriaga K
    PLoS Pathog; 2019 Nov; 15(11):e1008122. PubMed ID: 31765434
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epstein-Barr virus-transformed B-cells as efficient antigen presenting cells to propagate Aspergillus-specific cytotoxic T-lymphocytes.
    Ramadan G
    Egypt J Immunol; 2008; 15(1):145-57. PubMed ID: 20306679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of cytotoxic T cell epitopes within Epstein-Barr virus (EBV) oncogene latent membrane protein 1 (LMP1): evidence for HLA A2 supertype-restricted immune recognition of EBV-infected cells by LMP1-specific cytotoxic T lymphocytes.
    Khanna R; Burrows SR; Nicholls J; Poulsen LM
    Eur J Immunol; 1998 Feb; 28(2):451-8. PubMed ID: 9521052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulation of human cell engraftment and development of EBV-related lymphoproliferative disorders in Hu-PBL-scid mice.
    Wagar EJ; Cromwell MA; Shultz LD; Woda BA; Sullivan JL; Hesselton RM; Greiner DL
    J Immunol; 2000 Jul; 165(1):518-27. PubMed ID: 10861091
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recognition of Epstein-Barr virus-associated gastric carcinoma cells by cytotoxic T lymphocytes induced in vitro with autologous lymphoblastoid cell line and LMP2-derived, HLA-A24-restricted 9-mer peptide.
    Okugawa K; Itoh T; Kawashima I; Takesako K; Mazda O; Nukaya I; Yano Y; Yamamoto Y; Yamagishi H; Ueda Y
    Oncol Rep; 2004 Oct; 12(4):725-31. PubMed ID: 15375491
    [TBL] [Abstract][Full Text] [Related]  

  • 20. T cell repertoire and Epstein-Barr virus-specific T cell response in chronic active Epstein-Barr virus infection: a case study.
    Gallot G; Hamidou MA; Clémenceau B; Gaschet J; Tiberghien P; Ferrand C; Vivien R; Barbarot S; Coste-Burel M; Moreau A; Vié H
    Clin Immunol; 2006 Apr; 119(1):79-86. PubMed ID: 16386957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.